ND-0612 is under clinical development by Mitsubishi Tanabe Pharma and currently in Pre-Registration for Parkinson’s Disease. According to GlobalData, Pre-Registration drugs for Parkinson’s Disease have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how ND-0612’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ND-0612 overview
ND-0612 is under development as an adjunct to oral levodopa for the treatment of moderate to severe Parkinson's disease. The drug candidate is a liquid fixed dose combination of levodopa and carbidopa administered through a patch-pump or belt pump to deliver controlled dose continuously as subcutaneous infusion. It is formulated as both high dose (ND-0612H) and low dose (ND-0612L) liquid formulation. The drug candidate acts by targeting dopa decarboxylase and dopaminergic receptors (D1, D2, D3, D4 and D5).
Mitsubishi Tanabe Pharma overview
Mitsubishi Tanabe Pharma (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.
For a complete picture of ND-0612’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.